Table 3.

AEs reported by ≥2 healthy subjects in study 2

AE, n (%)	Single-dose phase				Multiple-dose phase
	AQW051, mg			Placebo	AQW051, mg			Placebo
	2.5 (N = 6)	15 (N = 6)	75 (N = 6)	(N = 6)	2.5 (N = 18)	15 (N = 18)	75 (N = 12)	(N = 16)
Any	3 (50.0)	2 (33.3)	2 (33.3)	1 (16.7)	12 (66.7)	5 (27.8)	8 (66.7)	4 (25.0)
Abnormal dreams	0	0	0	0	2 (11.1)	0	0	0
Constipation	1 (16.7)	0	0	0	2 (11.1)	0	0	0
Diarrhoea	1 (16.7)	0	0	1 (16.7)	2 (11.1)	0	0	0
Dizziness	0	0	1 (16.7)	0	3 (16.7)	1 (5.6)	2 (16.7)	0
Dizziness postural	0	0	0	0	2 (11.1)	0	0	0
Headache	0	2 (33.3)	0	0	2 (11.1)	2 (11.1)	2 (16.7)	1 (6.3)
Nausea	0	0	0	0	4 (22.2)	0	1 (8.3)	0
Pharyngolaryngeal pain	0	0	0	0	2 (11.1)	0	1 (8.3)	1 (6.3)
Somnolence	0	0	0	0	2 (11.1)	0	1 (8.3)	1 (6.3)